自身免疫与慢阻肺:临床意义
本文综述自身免疫在稳定期慢阻肺发病机制中的作用。吸烟是西方化国家超过90%慢阻肺病例的原因,但仅部分长期重度吸烟者80岁前出现症状性慢阻肺。细胞和抗体介导的自身免疫可能参与稳定期慢阻肺发病,羰基化修饰蛋白可能驱动自身免疫并导致小气道异常甚至肺气肿,但人类中自身免疫与慢阻肺机制的因果关系尚未确立。
要点
- 自身免疫可能参与稳定期慢阻肺发病,但因果关系未确立。
- 羰基化修饰蛋白可能驱动自身免疫并导致小气道异常和肺气肿。
- 血清自身抗体作为预测临床表型或疾病进展的生物标志物有前景。
核心结论
- 细胞和抗体介导的自身免疫可能在稳定期慢阻肺发病机制中起根本作用,但人类中自身免疫与慢阻肺机制之间的因果关系尚未牢固确立。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- 西方化国家超过90%的慢阻肺病例由长期吸烟引起,但仅部分长期重度吸烟者80岁前出现症状性慢阻肺。
- 慢阻肺以下气道异常免疫反应为特征,其进展与先天性和适应性炎症免疫细胞浸润肺组织形成淋巴滤泡相关。
- 羰基化修饰蛋白可能驱动慢阻肺自身免疫,导致特征性小气道异常,甚至参与肺气肿发病。
- 自身免疫反应对慢阻肺急性加重发病的潜在贡献仍在研究中。
临床怎么用
- 许多靶向自身免疫反应的药物已可用,其对照临床试验结果值得关注。
- 测量特异性血清自身抗体作为预测稳定期慢阻肺临床表型或进展的生物标志物具有前景。
局限性
- 人类中自身免疫与慢阻肺机制之间的因果关系尚未牢固确立。
- 自身免疫反应对慢阻肺急性加重发病的贡献仍在研究中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COPD is a leading cause of morbidity and mortality worldwide. Long-term cigarette smoking is the cause of > 90% of COPD cases in Westernized countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by age 80. COPD is characterized by an abnormal immune response in the lower airways, and its progression is associated with infiltration of the lung by innate and adaptive inflammatory immune cells that form lymphoid follicles. There is growing evidence that both cellular- and antibody-mediated autoimmunity has a fundamental role in the pathogenesis of stable COPD. In particular, carbonyl-modified proteins may help to drive autoimmunity in COPD and cause the characteristic small airways abnormalities and even contribute to the pathogenesis of pulmonary emphysema. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable patients with COPD has been identified, no cause-and-effect relationship between autoimmunity and the mechanisms of COPD has been firmly established in man. As such, the potential contribution of an autoimmune response to the pathogenesis of COPD exacerbation is still being investigated and represents an area of active research. Many drugs targeting autoimmune responses are already available, and the results of controlled clinical trials are awaited with great interest. The potential for measuring specific serum autoantibodies as biomarkers to predict clinical phenotypes or progression of stable COPD is promising.
引用
- Caramori G, Ruggeri P, Di Stefano A, et al. Autoimmunity and COPD: Clinical Implications. Chest. 2017. PMID: 29126842. doi:10.1016/j.chest.2017.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。